close
This ad will auto close in 10 seconds
Investor wealth surges over Rs 50 lakh crore in 3 years

Investor wealth surges over Rs 50 lakh crore in 3 years

Investor wealth has surged by over Rs 50 lakh crore since the Modi government was voted to power three years ago, with the Sensex surging to its lifetime high of 31,074.07 on Friday.

Cipla shares down 3%; mcap dips Rs 1,003 crore post Q4 results

Shares of pharma major Cipla on Friday fell by 3 percent after the company reported a consolidated net loss of Rs 61.79 crore for the March quarter.

Cipla gets USFDA nod for generic HIV drug

Cipla gets USFDA nod for generic HIV drug

Cipla has received approval from the US health regulator for its generic Abacavir and Lamivudine tablets used for treatment of HIV infection.

634 drugs on NPPA's price ceiling non-compliant list

634 drugs on NPPA's price ceiling non-compliant list

As many as 634 drugs of various strengths produced by firms, including Cipla, Abbott, Astrazeneca and Dr Reddy's, are "suspected" to be non-compliant with ceiling prices as notified by NPPA.

Cipla initiates campaign for a pollution free Delhi; starts #saveyourlungsdilli

Cipla initiates campaign for a pollution free Delhi; starts #saveyourlungsdilli

According to a TGI Survey, 34 percent (approx five million) of Delhi people are suffering respiratory problems including Asthma, Bronchitis, and Chronic Obstructive Pulmonary Disease. 

Cipla appoints Ireena Vittal as independent director

Drug major Cipla on Tuesday said it has appointed Ireena Vittal as an independent director on its board with effect from December 1, 2016.

Cipla gets four USFDA observations for three Goa facilities; stocks fall over 3%

Cipla gets four USFDA observations for three Goa facilities; stocks fall over 3%

Drug firm Cipla on Friday said the US health regulator has issued four observations across its three manufacturing facilities in Goa after the inspection.

Drug firms facing challenging times due to price control: Cipla

Drug firms facing challenging times due to price control: Cipla

 Drug companies are facing a tough environment due to the government bringing more products under the price control policy as also tightening of registration procedure that has impacted time to market newer products, Cipla Chairman YK Hamied has said.

Cipla, Godrej recognised in Fortune 'Change the World' list

Cipla, Godrej recognised in Fortune 'Change the World' list

India's pharmaceutical giant Cipla and consumer goods conglomerate Godrej have been recognised by Fortune magazine in a list of global firms changing the world for the good and having a positive social impact through their activities.

Cipla, Godrej Consumer Products in Fortune 'Change the World' list

Two Indian companies -- Cipla and Godrej Consumer Products -- have been named in Fortune magazine's list of top 50 companies that are addressing global social problems as part of their core business strategy.

Lupin Pharmaceuticals is India's most reputed pharma brand; Sun Pharma second

Lupin Pharmaceuticals is India's most reputed pharma brand; Sun Pharma second

Mumbai-based Lupin Pharmaceuticals is India`s most reputed pharmaceutical brand, said a report by Bluebytes, a leading media-analytics company on Wednesday.

FDCs banned over safety & efficacy concerns: Centre tells HC

The hearing in the matter would continue on April 4.  

Delhi High Court to resume hearing on petitions against Centre's ban on drugs

Delhi High Court to resume hearing on petitions against Centre's ban on drugs

Delhi High Court is likely to resume today the hearing on petitions by over 30 pharmaceutical majors, including Pfizer, Glenmark, Procter and Gamble (P&G) and Cipla, challenging the government's decision to ban sale of some of their fixed dose combination medicines.

Cipla invests additional $ 3mn in US's Chase Pharmaceuticals

Drug firm Cipla Ltd has made an additional investment of USD 3 million in US-based Chase Pharmaceuticals engaged in developing novel approaches to improve treatments for Alzheimer's disease.

Antim Baazi: Action In Cairn India, Reliance & Cipla

Check out the action going in Cairn India, Reliance & Cipla.

Cipla sets up 6-member leadership team

Drug major Cipla on Thursday announced the creation of a 6-member 'Management Council' that will be the apex executive leadership team for the company.

Cipla launches generic hepatitis C drug in India

Drug major Cipla has launched generic tablets used for treating of hepatitis C under the brand name 'Hepcvir-L' costing Rs 25,000 for a bottle of 28 tablets in India.

Hot Stocks: Expert on Gabriel India, Cipla

Know what our expert has to say about
Zee Business, India's first 24-hour Hindi business channel, was conceived to offer 'information' and 'insight' and bring business and economy coverage to you in your own language.

Cipla infringing Roche's patent in lung cancer drug: HC

In a setback to Cipla, the Delhi High Court on Friday held that the Indian drug major was infringing Swiss pharmaceutical company Hoffman-La Roche's patent in lung cancer drug erlotinib hydrochloride, sold under the name of Tarceva.

Cipla Q2 net profit at Rs 431 crore;lower growth expected in H2

Net sales of the company rose to Rs 3,361.73 crore for in the second quarter of current fiscal.